5 active not recruiting, 5 completed, 3 terminated, 2 recruiting. 11 Phase 2, 6 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 3, Completed 3, Recruiting 2, Terminated 2, Not yet recruiting 1 |
| Phase 1 | 6 | Active not recruiting 3, Terminated 3 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Philadelphia Chromosome Positive: new trials by email Literature Review of Philadelphia Chromosome Positive trials Research Report on Philadelphia Chromosome Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase Dasatinib, Decitabine and Cedazuridine - Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2021-10-21 | 2026-10-02 |
| Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia Blinatumomab, Laboratory Biomarker Analysis, Pembrolizumab - CD19 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 36 | 2019-08-02 | 2025-05-30 |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers Cladribine, Cytarabine, Dexrazoxane Hydrochloride - Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2018-09-19 | 2026-05-22 |
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia ADCT-602 - Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2018-08-24 | 2025-12-12 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Dexamethasone, Ponatinib Hydrochloride, Rituximab - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2018-06-26 | 2025-05-08 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 | Terminated | University of Southern California | 3 | 2018-05-09 | 2021-11-30 |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia Blinatumomab, Cytarabine, Methotrexate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 90 | 2017-11-29 | 2026-05-20 |
| Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 | Active not recruiting | Stanford University | 33 | 2017-10-20 | 2026-06-30 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 | Active not recruiting | Stanford University | 56 | 2017-09-01 | 2025-11-18 |
| Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia Blinatumomab, Ibrutinib - Adult B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive | Phase 2 | Completed | University of California, Davis | 19 | 2017-06-27 | 2026-06-09 |
| Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease Blinatumomab, TKI - Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 37 | 2015-09-14 | 2026-09-25 |
| Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dexamethasone - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 88 | 2011-10-05 | 2026-10-06 |
| Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma | Phase 3 | Completed | Children's Oncology Group | 9350 | 2010-08-11 | 2026-05-28 |
| Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Nilotinib - Philadelphia Chromosome Positive, Chronic Myelogenous Leukemia in Chronic Phase | Phase 4 | Completed | Novartis Pharmaceuticals | 45 | 2009-12-01 | 2016-04-08 |
| Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. Cyclophosphamide, Cytarabine, Dasatinib - Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression | Phase 2 | Completed | M.D. Anderson Cancer Center | 107 | 2006-09-28 | 2025-02-17 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Blast Crisis (5) · Burkitt Lymphoma (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Neoplasm, Residual (3) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myeloid, Acute (2) · Down Syndrome (1) · Leukemia, Myeloid, Chronic-Phase (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Sarcoma, Myeloid (1)
Hemic and Lymphatic Diseases (16) · Neoplasms (16) · Neoplasms by Histologic Type (16) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Lymphatic Diseases (13) · Lymphoproliferative Disorders (13) · Hematologic Diseases (12) · Leukemia (12) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Leukemia, Lymphoid (9) · Bone Marrow Diseases (8) · Chronic Disease (8) · Disease Attributes (8)
Cytarabine (6) · Cyclophosphamide (5) · blinatumomab (5) · Calcium Dobesilate (4) · Dexamethasone (4) · Methotrexate (4) · N,N-dicyclohexyl-isoborneol-10-sulfonamide (4) · Vincristine (4) · auricularum (4) · dexamethasone 21-phosphate (4) · dexamethasone acetate (4) · merphos (4) · Doxorubicin (3) · ponatinib (3) · CT-P10 (2)
M.D. Anderson Cancer Center (9) · Stanford University (2) · Children's Oncology Group (1) · City of Hope Medical Center (1) · Novartis Pharmaceuticals (1) · University of California, Davis (1) · University of Southern California (1)
United States (15) · Australia (1) · Canada (1) · Ireland (1) · Japan (1) · New Zealand (1) · Puerto Rico (1) · Switzerland (1)
Elias Jabbour (4) · Akil Merchant, MD (1) · Anne L Angiolillo (1) · Brian Jonas (1) · Crystal Mackall (1) · Elias J Jabbour, MD (1) · Farhad Ravandi-Kashani (1) · Farhad Ravandi-Kashani, MD (1) · Lihua Budde (1) · Lori Muffly, MD, MS (1) · Maro Ohanian (1) · Nitin Jain (1)
PMID 35622074, PMID 41671463, PMID 20466853, PMID 26432046, PMID 27771544, PMID 30501869, PMID 32929049, PMID 33411585, PMID 34312556, PMID 34515338, PMID 34889384, PMID 35713551, PMID 36402146, PMID 36600670, PMID 37890117, PMID 38324336, PMID 38968138, PMID 39028925, PMID 39121442, PMID 40315406, PMID 40369607
P30CA014089 (1), P30CA016672 (1), P30CA093373 (1), U10CA098543 (1), U10CA180886 (1)